EcoR1 Makes a Timely Bet

Mirati’s deal with Bristol Myers Squibb came too late to save life sciences funds, which suffered through another rough month in September.

Art_EcoR1_1016.jpg

Getty Images

Now this is what you call market timing.

Life sciences hedge fund EcoR1 Capital disclosed that as of September 22 it had initiated a stake of nearly 5.75 million shares of Mirati Therapeutics, making it the second-largest shareholder, with about 9.8 percent of the commercial-stage oncology company’s shares.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related